USD 0.1
(0.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 11823.24 Billion USD | 11.77% |
2022 | 456.21 Million USD | -5.79% |
2021 | 484.27 Million USD | 6.74% |
2020 | 453.69 Million USD | -5.44% |
2019 | 479.8 Million USD | 7.82% |
2018 | 445 Million USD | -5.41% |
2017 | 470.46 Million USD | 0.89% |
2016 | 466.3 Million USD | 10.59% |
2015 | 421.65 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 120.48 Million USD | -4.74% |
2024 Q3 | 148.53 Million USD | 2533438.72% |
2024 Q1 | 126.48 Million USD | 4.68% |
2023 Q4 | 120.82 Million USD | -5.36% |
2023 FY | 509.93 Million USD | 11.77% |
2023 Q1 | 133.07 Million USD | 18.93% |
2023 Q2 | 134.7 Million USD | 1.23% |
2023 Q3 | 127.67 Million USD | -5.22% |
2022 Q2 | 120.82 Million USD | -2.26% |
2022 FY | 456.21 Million USD | -5.79% |
2022 Q4 | 111.88 Million USD | -2.97% |
2022 Q3 | 115.3 Million USD | -4.57% |
2022 Q1 | 123.62 Million USD | 1.3% |
2021 Q1 | 114.09 Million USD | 0.0% |
2021 FY | 484.27 Million USD | 6.74% |
2021 Q4 | 122.04 Million USD | -2.78% |
2021 Q3 | 125.53 Million USD | 5.56% |
2021 Q2 | 118.91 Million USD | 4.23% |
2020 FY | 453.69 Million USD | -5.44% |
2019 FY | 479.8 Million USD | 7.82% |
2018 FY | 445 Million USD | -5.41% |
2017 FY | 470.46 Million USD | 0.89% |
2016 FY | 466.3 Million USD | 10.59% |
2015 FY | 421.65 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
AstraZeneca PLC | 29.57 Billion USD | -39873.107% |
Bristol-Myers Squibb Company PFD CONV 2 | 17.07 Billion USD | -69159.244% |
CSPC Pharmaceutical Group Limited | 2.14 Billion USD | -550596.598% |
Clarus Therapeutics Holdings, Inc. | 50.96 Million USD | -23196834.477% |
Novartis AG | 24.87 Billion USD | -47438.28% |